Achilles Therapeutics plc (ACHL)

Market Cap	71.64M
Revenue (ttm)	n/a
Net Income (ttm)	-65.35M
Shares Out	39.31M
EPS (ttm)	6.35
PE Ratio	0.27
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,863
Open	1.75
Previous Close	1.75
Day's Range	1.71 - 1.85
52-Week Range	1.58 - 5.65
Beta	n/a
Analysts	Buy
Price Target	15.91 (+830.4%)
Earnings Date	Nov 8, 2022

About ACHL

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carci...

• Industry: Biotechnology
• IPO Date: Mar 31, 2021
• Employees: 242
• Stock Exchange: NASDAQ
• Ticker Symbol: ACHL

Analyst Forecast

According to 12 analysts, the average rating for ACHL stock is "Buy." The 12-month stock price forecast is 15.91, which is an increase of 830.41% from the latest price.

Price Target

$15.91

(830.41% upside)

Analyst Consensus: Buy